Anxiety
Articles about Anxiety
From Croatia to MAHA: How an unapproved drug became the next hot peptide
BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.
Addex Announces Publication Of Preclinical Data Supporting Potential Of Mglu7 Negative Allosteric Modulators To Transform Anxiety And Fear-Related Disorder Treatment
(MENAFN - GlobeNewsWire - Nasdaq) Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN ...
Global Sleep Disorder Market Report 2026 Business Expansion, Key Growth Drivers, And Trends Through 2030
(MENAFN - EIN Presswire) EINPresswire/ -- Understanding the growing importance of sleep health reveals why the sleep disorder market is expanding so rapidly. With an increasing number of people ...
A Guide to Proven Anxiety Treatment Options for 2025
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen Therapeutics, Inc. Investors to Secure ...
NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) --
Incannex Healthcare Announces Formation Of Clinical Advisory Board For PSX-001 Program
(MENAFN - GlobeNewsWire - Nasdaq) Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of developmentMELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) ...
Lumateperone Shows Broad Symptom Benefit for MDD, With Michael E. Thase, MD
Using AI for advice or other personal reasons linked to depression and anxiety
People who interact with chatbots for emotional support or other personal reasons are more likely to report symptoms of depression or anxiety, a new study finds. The researchers from Mass General Brigham surveyed 20,847 mostly white men and women in the United States about their AI usage and mental health symptoms. In the survey, published Wednesday in JAMA Network Open, 10.3% of participants reported using artificial intelligence “at least daily” and 5% reported using it “multiple times per day
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure ...
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) --
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
Market Analysis by covering: CorMedix Inc, ATAI Beckley Inc, Evommune Inc. Read 's Market Analysis on Investing.com
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...